SM
ATNM icon

Sabby Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Sabby Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,921
Closed -$2.05M – 93
2022
Q4 		$2.05M Sell
1,921
-222
-10% -$2.25K 1.79% 5
2022
Q3 		$1.58M Buy
2,143
+379
+21% +$2.36K 2% 11
2022
Q2 		$848K Buy
1,764
+293
+20% +$1.66K 0.58% 35
2022
Q1 		$752K Sell
1,471
-2,530
-63% -$13.3K 0.11% 52
2021
Q4 		$2.4M Buy
4,001
+244
+6% +$1.83K 0.35% 49
2021
Q3 		$3.33M Buy
+3,757
New +$26.1K 0.45% 31
2021
Q2 		– Sell
-100
Closed -$76K – 165
2021
Q1 		$76K Sell
100
-281
-74% -$2.39K 0.01% 151
2020
Q4 		$297K Buy
381
+217
+132% +$2.36K 0.06% 75
2020
Q3 		$159K Buy
+164
New +$1.81K 0.02% 105

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sabby Management's ATNM Position: Q1 2022 in Review

Sabby Management sold out of Actinium Pharmaceuticals (ATNM) in Q1 2022, closing a stake of 73,366 shares — an estimated $386K sold.

Sabby Management first reported a position in ATNM in Q3 2015 and held it in 12 quarters. The position peaked at $2.05M in Q2 2019. 38 funds tracked by Wall St. Rank hold ATNM as of Q1 2022.

  • Sabby Management reported no remaining Actinium Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Sabby Management sold 73,366 Actinium Pharmaceuticals shares in Q1 2022, an estimated $386K.
  • Sabby Management first reported a position in Actinium Pharmaceuticals in Q3 2015 and held it in 12 quarters.
  • Sabby Management's Actinium Pharmaceuticals position peaked at $2.05M in Q2 2019.
  • 38 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2022.

Based on Sabby Management's 13F filing for Q1 2022, filed 16 May 2022.